Skip to Content
Merck
CN

SML4040

Sigma-Aldrich

Danusertib

≥98% (HPLC)

Synonym(s):

PHA739358, 4-(4-Methyl-1-piperazinyl)-N-[1,4,5,6-tetrahydro-5-[(2R)-2-methoxy-2-phenylacetyl]pyrrolo[3,4-c]pyrazol-3-yl]benzamide, 4-(4-Methyl-1-piperazinyl)-N-[1,4,5,6-tetrahydro-5-[(2R)-methoxyphenylacetyl]pyrrolo[3,4-c]pyrazol-3-yl]-benzamide, N-[5-((2R)-2-Methoxy-2-phenylethanoyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide, N-[5-(2R)-2-Methoxy-2-phenylacetyl)-1,4,5,6-tetrahydropyrrolo [3,4-c]pyrazol-3-yl]-4-(4-methylpiperazin-1-yl)-benzamide, PHA 739358, PHA-739358

Sign Into View Organizational & Contract Pricing

Select a Size


About This Item

Empirical Formula (Hill Notation):
C26H30N6O3
CAS Number:
Molecular Weight:
474.55
MDL number:
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Quality Level

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

-10 to -25°C

SMILES string

O=C(C1=CC=C(N2CCN(CC2)C)C=C1)NC3=NNC4=C3CN(C([C@@H](C5=CC=CC=C5)OC)=O)C4

InChI

1S/C26H30N6O3/c1-30-12-14-31(15-13-30)20-10-8-19(9-11-20)25(33)27-24-21-16-32(17-22(21)28-29-24)26(34)23(35-2)18-6-4-3-5-7-18/h3-11,23H,12-17H2,1-2H3,(H2,27,28,29,33)/t23-/m1/s1

InChI key

XKFTZKGMDDZMJI-HSZRJFAPSA-N

Biochem/physiol Actions

Potent ATP site-targeting kinase inhibitor against aurora A/B/C, FGFR1, Abl, Ret, and TrkA with anti-cancer efficacy in cultures and in vivo.
Danusertib (PHA-739358) is a potent ATP site-targeting aurora kinase inhibitor (IC50 = 13 nM/A, 79 nM/B, 61 nM/C; [ATP] = 2 Km, [substrate] = 5 Km) with additional potency against FGFR1, Abl, Ret, and TrkA (IC50 = 47, 25, 31, 31 nM, respectively; [ATP] = 2 Km, [substrate] = 5 Km). Danusertib exhibits antiproliferation activity in cancer cultures (IC50 20-300 nM among 15 cancer cell lines) and antitumor efficacy in mice with human cancer xenografts in vivo via i.v. (30 mg/kg q.d. or b.i.d.) or i.p. (15 mg/kg b.i.d.).

Storage Class Code

11 - Combustible Solids

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Daniel Benten et al.
Neoplasia (New York, N.Y.), 11(9), 934-944 (2009-09-03)
Patients with advanced stages of hepatocellular carcinoma (HCC) face a poor prognosis. Although encouraging clinical results have been obtained with multikinase inhibitor sorafenib, the development of improved therapeutic strategies for HCC remains an urgent goal. Aurora kinases are key regulators
Michele Modugno et al.
Cancer research, 67(17), 7987-7990 (2007-09-07)
Mutations in the kinase domain of Bcr-Abl are the most common cause of resistance to therapy with imatinib in patients with chronic myelogenous leukemia (CML). Second-generation Bcr-Abl inhibitors are able to overcome most imatinib-resistant mutants, with the exception of the
Patrizia Carpinelli et al.
Molecular cancer therapeutics, 6(12 Pt 1), 3158-3168 (2007-12-20)
PHA-739358 is a small-molecule 3-aminopyrazole derivative with strong activity against Aurora kinases and cross-reactivities with some receptor tyrosine kinases relevant for cancer. PHA-739358 inhibits all Aurora kinase family members and shows a dominant Aurora B kinase inhibition-related cellular phenotype and

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service